Skip to main content
SpringerLink
Log in

Chronic Obstructive Pulmonary Disease in Older Patients

  • Chapter
  • First Online:
Aging and Lung Disease

Part of the book series: Respiratory Medicine ((RM))

  • 1283 Accesses

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by progressive expiratory airflow limitation that is not fully reversible [1]. It is a chronic condition resulting from an abnormal inflammatory response to noxious particles or gases, such as tobacco smoke. Although the lungs are the primary organ affected by inflammation, significant inflammation also involves the cardiovascular, musculoskeletal, and neuropsychiatric systems [1]. The elderly are particularly at risk for developing COPD due to aging-associated changes in physiologic and immune function.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2009. http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=2180. Accessed 17 July 2010.

  2. Mannino DM et al. Chronic obstructive pulmonary disease surveillance – United States, 1971–2000. MMWR Surveill Summ. 2002;51(6):1–16.

    Google Scholar 

  3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498–504.

    Article  PubMed  CAS  Google Scholar 

  4. Halbert RJ et al. Interpreting COPD prevalence estimates: what is the true burden of disease? Chest. 2003;123(5):1684–92.

    Article  PubMed  CAS  Google Scholar 

  5. Menezes AM et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet. 2005;366(9500):1875–81.

    Article  PubMed  Google Scholar 

  6. Regional COPD Working Group. COPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation model. Respirology. 2003;8(2):192–8.

    Article  Google Scholar 

  7. Buist AS et al. International variation in the prevalence of COPD (the BOLD Study): a ­population-based prevalence study. Lancet. 2007;370(9589):741–50.

    Article  PubMed  Google Scholar 

  8. Fukuchi Y et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology. 2004;9(4):458–65.

    Article  PubMed  Google Scholar 

  9. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet. 2006;367(9518): 1216–9.

    Article  PubMed  Google Scholar 

  10. Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest. 2001;119(6): 1691–5.

    Article  PubMed  CAS  Google Scholar 

  11. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease ­heterogeneity. Chest. 2002;121(5 Suppl):121S–6S.

    Article  PubMed  Google Scholar 

  12. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med. 2009;360(14):1418–28.

    Article  PubMed  CAS  Google Scholar 

  13. Foster TS et al. Assessment of the economic burden of COPD in the U.S.: a review and ­synthesis of the literature. COPD. 2006;3(4):211–8.

    Article  PubMed  Google Scholar 

  14. Menzin J et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med. 2008;102(9):1248–56.

    Article  PubMed  Google Scholar 

  15. Sharma G, Goodwin J. Effect of aging on respiratory system physiology and immunology. Clin Interv Aging. 2006;1(3):253–60.

    Article  PubMed  CAS  Google Scholar 

  16. Estenne M, Yernault JC, De Troyer A. Rib cage and diaphragm-abdomen compliance in humans: effects of age and posture. J Appl Physiol. 1985;59(6):1842–8.

    PubMed  CAS  Google Scholar 

  17. Sharma G, Hanania NA, Shim YM. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6(7): 573–80.

    Article  PubMed  CAS  Google Scholar 

  18. Beasley MB. Smoking-related small airway disease – a review and update. Adv Anat Pathol. 2010;17(4):270–6.

    Article  PubMed  Google Scholar 

  19. Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence. Thorax. 2010; 65(10): 930–6.

    Article  PubMed  Google Scholar 

  20. Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary ­disease. N Engl J Med. 2009;360(23):2445–54.

    Article  PubMed  CAS  Google Scholar 

  21. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359(22):2355–65.

    Article  PubMed  CAS  Google Scholar 

  22. Bandi V et al. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med. 2001;164(11):2114–9.

    PubMed  CAS  Google Scholar 

  23. Murphy TF et al. Persistent colonization by Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;170(3):266–72.

    Article  PubMed  Google Scholar 

  24. Sethi S et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(9):991–8.

    Article  PubMed  Google Scholar 

  25. Retamales I et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med. 2001;164(3):469–73.

    PubMed  CAS  Google Scholar 

  26. O’Donnell DE et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc. 2007;4(2):145–68.

    Article  PubMed  Google Scholar 

  27. Rock LK, Schwartzstein RM. Mechanisms of dyspnea in chronic lung disease. Curr Opin Support Palliat Care. 2007;1(2):102–8.

    Article  PubMed  Google Scholar 

  28. Johnson BD, Badr MS, Dempsey JA. Impact of the aging pulmonary system on the response to exercise. Clin Chest Med. 1994;15(2):229–46.

    PubMed  CAS  Google Scholar 

  29. O’Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis. 1993;148(5):1351–7.

    PubMed  Google Scholar 

  30. Hannink JD et al. Dynamic hyperinflation during daily activities: does COPD global initiative for chronic obstructive lung disease stage matter? Chest. 2010;137(5):1116–21.

    Article  PubMed  Google Scholar 

  31. Rennard S et al. Impact of COPD in North America and Europe in 2000: subjects’ perspective of Confronting COPD International Survey. Eur Respir J. 2002;20(4):799–805.

    Article  PubMed  CAS  Google Scholar 

  32. Hirayama F et al. Physical activity of patients with chronic obstructive pulmonary disease: implications for pulmonary rehabilitation. J Cardiopulm Rehabil Prev. 2008;28(5):330–4.

    PubMed  Google Scholar 

  33. Pitta F et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(9):972–7.

    Article  PubMed  Google Scholar 

  34. Feary JR et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65(11):956–62.

    Article  PubMed  Google Scholar 

  35. Sidney S et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128(4):2068–75.

    Article  PubMed  Google Scholar 

  36. Anthonisen NR et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994; 272(19):1497–505.

    Article  PubMed  CAS  Google Scholar 

  37. Celli BR et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–12.

    Article  PubMed  CAS  Google Scholar 

  38. McGarvey LP et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62(5):411–5.

    Article  PubMed  Google Scholar 

  39. Zvezdin B et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest. 2009;136(2):376–80.

    Article  PubMed  Google Scholar 

  40. Lange P et al. Cardiovascular morbidity in COPD: a study of the general population. COPD. 2010;7(1):5–10.

    Article  PubMed  Google Scholar 

  41. McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med. 2009;180(8):692–700.

    Article  PubMed  CAS  Google Scholar 

  42. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009;218(1):7–29.

    Article  PubMed  Google Scholar 

  43. Decramer M et al. Systemic effects of COPD. Respir Med. 2005;99(Suppl B):S3–10.

    Article  PubMed  Google Scholar 

  44. Schols AM et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1791–7.

    PubMed  CAS  Google Scholar 

  45. Graat-Verboom L et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009;34(1):209–18.

    Article  PubMed  CAS  Google Scholar 

  46. Bon JM et al. Plasma inflammatory mediators associated with bone metabolism in COPD. COPD. 2010;7(3):186–91.

    Article  PubMed  Google Scholar 

  47. Lawlor DA, Patel R, Ebrahim S. Association between falls in elderly women and chronic diseases and drug use: cross sectional study. BMJ. 2003;327(7417):712–7.

    Article  PubMed  Google Scholar 

  48. Roig M et al. Falls in patients with chronic obstructive pulmonary disease: a call for further research. Respir Med. 2009;103(9):1257–69.

    Article  PubMed  Google Scholar 

  49. Madsen H, Brixen K, Hallas J. Screening, prevention and treatment of osteoporosis in patients with chronic obstructive pulmonary disease – a population-based database study. Clin Respir J. 2010;4(1):22–9.

    Article  PubMed  Google Scholar 

  50. Graat-Verboom L et al. Correlates of osteoporosis in chronic obstructive pulmonary disease: an underestimated systemic component. Respir Med. 2009;103(8):1143–51.

    Article  PubMed  Google Scholar 

  51. Langmore SE et al. Predictors of aspiration pneumonia in nursing home residents. Dysphagia. 2002;17(4):298–307.

    Article  PubMed  Google Scholar 

  52. Gross RD et al. The coordination of breathing and swallowing in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(7):559–65.

    Article  PubMed  Google Scholar 

  53. Terada K et al. Abnormal swallowing reflex and COPD exacerbations. Chest. 2010;137(2): 326–32.

    Article  PubMed  Google Scholar 

  54. Kobayashi S, Kubo H, Yanai M. Impairment of the swallowing reflex in exacerbations of COPD. Thorax. 2007;62(11):1017.

    Article  PubMed  Google Scholar 

  55. Mokhlesi B et al. Oropharyngeal deglutition in stable COPD. Chest. 2002;121(2):361–9.

    Article  PubMed  Google Scholar 

  56. Dodd JW, Getov SV, Jones PW. Cognitive function in COPD. Eur Respir J. 2010;35(4): 913–22.

    Article  PubMed  CAS  Google Scholar 

  57. Grant I et al. Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease. Arch Intern Med. 1982;142(8):1470–6.

    Article  PubMed  CAS  Google Scholar 

  58. Stump TE, Callahan CM, Hendrie HC. Cognitive impairment and mortality in older primary care patients. J Am Geriatr Soc. 2001;49(7):934–40.

    Article  PubMed  CAS  Google Scholar 

  59. Antonelli-Incalzi R et al. Drawing impairment predicts mortality in severe COPD. Chest. 2006;130(6):1687–94.

    Article  PubMed  Google Scholar 

  60. Ranieri P et al. Predictors of 6-month mortality in elderly patients with mild chronic obstructive pulmonary disease discharged from a medical ward after acute nonacidotic exacerbation. J Am Geriatr Soc. 2008;56(5):909–13.

    Article  PubMed  Google Scholar 

  61. Allen SC et al. Acquisition and short-term retention of inhaler techniques require intact executive function in elderly subjects. Age Ageing. 2003;32(3):299–302.

    Article  PubMed  Google Scholar 

  62. Schneider C et al. COPD and the risk of depression. Chest. 2010;137(2):341–7.

    Article  PubMed  Google Scholar 

  63. Julian LJ et al. Screening for depression in chronic obstructive pulmonary disease. COPD. 2009;6(6):452–8.

    Article  PubMed  Google Scholar 

  64. van den Bemt L et al. The risk for depression comorbidity in patients with COPD. Chest. 2009;135(1):108–14.

    Article  PubMed  Google Scholar 

  65. Yohannes AM et al. Depression and anxiety in chronic heart failure and chronic obstructive pulmonary disease: prevalence, relevance, clinical implications and management principles. Int J Geriatr Psychiatry. 2010;25(12):1209–21.

    Article  PubMed  CAS  Google Scholar 

  66. An L et al. Predictive validity of BODE index for anxious and depressive symptoms in patients with chronic obstructive pulmonary disease. Chin Med J (Engl). 2010;123(14): 1845–51.

    Google Scholar 

  67. Balcells E et al. Factors affecting the relationship between psychological status and quality of life in COPD patients. Health Qual Life Outcomes. 2010;8(27):108–16.

    Article  PubMed  Google Scholar 

  68. Lindberg A et al. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med. 2006;100(2):264–72.

    Article  PubMed  Google Scholar 

  69. Bridevaux PO et al. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax. 2008;63(9):768–74.

    Article  PubMed  Google Scholar 

  70. Pezzoli L et al. Quality of spirometric performance in older people. Age Ageing. 2003;32(1): 43–6.

    Article  PubMed  Google Scholar 

  71. Bellia V et al. Quality control of spirometry in the elderly. The SA.R.A. study. SAlute Respiration nell’Anziano  =  Respiratory Health in the Elderly. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1094–100.

    PubMed  CAS  Google Scholar 

  72. Allen SC, Yeung P. Inability to draw intersecting pentagons as a predictor of unsatisfactory spirometry technique in elderly hospital inpatients. Age Ageing. 2006;35(3):304–6.

    Article  PubMed  Google Scholar 

  73. Allen S et al. Predicting inadequate spirometry technique and the use of FEV1/FEV3 as an alternative to FEV1/FVC for patients with mild cognitive impairment. Clin Respir J. 2008;2(4):208–13.

    Article  PubMed  Google Scholar 

  74. Hurst JR et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–38.

    Article  PubMed  CAS  Google Scholar 

  75. Nishimura K et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest. 2002;121(5):1434–40.

    Article  PubMed  Google Scholar 

  76. Domingo-Salvany A et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(5):680–5.

    Article  PubMed  Google Scholar 

  77. Jones RC et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009;180(12):1189–95.

    Article  PubMed  Google Scholar 

  78. Puhan MA et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;374(9691): 704–11.

    Article  PubMed  Google Scholar 

  79. Chen JC, Mannino DM. Worldwide epidemiology of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 1999;5(2):93–9.

    Article  PubMed  CAS  Google Scholar 

  80. Scanlon PD et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000;161(2 Pt 1): 381–90.

    PubMed  CAS  Google Scholar 

  81. Taylor Jr DH et al. Benefits of smoking cessation for longevity. Am J Public Health. 2002;92(6):990–6.

    Article  PubMed  Google Scholar 

  82. Morgan MD, Britton JR. Chronic obstructive pulmonary disease 8: non-pharmacological management of COPD. Thorax. 2003;58(5):453–7.

    Article  PubMed  CAS  Google Scholar 

  83. Murray RP et al. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest. 1996;109(2):438–45.

    Article  PubMed  CAS  Google Scholar 

  84. Murray RP, Connett JE, Zapawa LM. Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study. Nicotine Tob Res. 2009;11(9):1076–82.

    Article  PubMed  Google Scholar 

  85. Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest. 2006;130(2):334–42.

    Article  PubMed  Google Scholar 

  86. Wagena EJ et al. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med. 2004;98(9):805–15.

    Article  PubMed  CAS  Google Scholar 

  87. Tashkin DP et al. Effects of varenicline on smoking cessation in mild-to-moderate COPD: a randomized controlled trial. Chest. 2011;139(3):591–9.

    Article  PubMed  Google Scholar 

  88. Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD. 2006;3(4):195–202.

    Article  PubMed  Google Scholar 

  89. Poole PJ, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006(1):CD002733.

    Google Scholar 

  90. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999;130(5):397–403.

    PubMed  CAS  Google Scholar 

  91. Nichol KL et al. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med. 1999;159(20):2437–42.

    Article  PubMed  CAS  Google Scholar 

  92. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24(8):1159–69.

    Article  PubMed  CAS  Google Scholar 

  93. Jefferson T et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366(9492):1165–74.

    Article  PubMed  CAS  Google Scholar 

  94. Feldman G et al. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a ­double-blind, randomised, 12-week study. BMC Pulm Med. 2010;10:11.

    Article  PubMed  CAS  Google Scholar 

  95. Dahl R et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol ­versus twice-daily formoterol in COPD. Thorax. 2010;65(6):473–9.

    Article  PubMed  Google Scholar 

  96. Vogelmeier C et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-­controlled blinded comparison with tiotropium. Respir Res. 2010;11(1):135.

    Article  PubMed  CAS  Google Scholar 

  97. Donohue JF et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182(2):155–62.

    Article  PubMed  CAS  Google Scholar 

  98. Tashkin DP et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54.

    Article  PubMed  CAS  Google Scholar 

  99. Stanbrook MB. ACP Journal Club. Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications. Ann Intern Med. 2009;150(2):JC1–7.

    Google Scholar 

  100. Anthonisen NR et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166(3):333–9.

    Article  PubMed  Google Scholar 

  101. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–50.

    Article  PubMed  CAS  Google Scholar 

  102. Celli B et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948–55.

    Article  PubMed  CAS  Google Scholar 

  103. Celli B et al. Cardiovascular safety of tiotropium in patients with COPD. Chest. 2010;137(1):20–30.

    Article  PubMed  CAS  Google Scholar 

  104. Ogale SS et al. Cardiovascular events associated with ipratropium bromide in COPD. Chest. 2010;137(1):13–9.

    Article  PubMed  CAS  Google Scholar 

  105. Burge PS et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–303.

    Article  PubMed  CAS  Google Scholar 

  106. Ernst P et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176(2):162–6.

    Article  PubMed  CAS  Google Scholar 

  107. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and ­progression. Am J Med. 2010;123(11):1001–6.

    Article  PubMed  CAS  Google Scholar 

  108. Ferguson GT et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009;136(6):1456–65.

    Article  PubMed  Google Scholar 

  109. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med. 2010;16(2):118–22.

    Article  PubMed  Google Scholar 

  110. Calverley PM et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.

    Article  PubMed  CAS  Google Scholar 

  111. Celli BR et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332–8.

    Article  PubMed  Google Scholar 

  112. Aaron SD et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146(8):545–55.

    PubMed  Google Scholar 

  113. Niewoehner DE. Clinical practice. Outpatient management of severe COPD. N Engl J Med. 2010;362(15):1407–16.

    Article  PubMed  CAS  Google Scholar 

  114. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354(9177):456–60.

    Article  PubMed  CAS  Google Scholar 

  115. Niewoehner DE et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340(25):1941–7.

    Article  PubMed  CAS  Google Scholar 

  116. Rabe KF et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–55.

    Article  PubMed  Google Scholar 

  117. Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 2001;134(7):595–9.

    PubMed  CAS  Google Scholar 

  118. Ram FS, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006(2):CD004403.

    Google Scholar 

  119. Rothberg MB et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2010;303(20):2035–42.

    Article  PubMed  CAS  Google Scholar 

  120. Stolz D et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131(1):9–19.

    Article  PubMed  CAS  Google Scholar 

  121. Schuetz P et al. Effect of procalcitonin-based guidelines vs. standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059–66.

    Article  PubMed  CAS  Google Scholar 

  122. Calverley PM et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685–94.

    Article  PubMed  CAS  Google Scholar 

  123. Calverley PM et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(2):154–61.

    Article  PubMed  CAS  Google Scholar 

  124. Rabe KF et al. Roflumilast – an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366(9485):563–71.

    Article  PubMed  CAS  Google Scholar 

  125. Fabbri LM et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009; 374(9691):695–703.

    Article  PubMed  CAS  Google Scholar 

  126. Decramer M et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005;365(9470):1552–60.

    Article  PubMed  CAS  Google Scholar 

  127. Couser Jr JI et al. Pulmonary rehabilitation improves exercise capacity in older elderly patients with COPD. Chest. 1995;107(3):730–4.

    Article  PubMed  Google Scholar 

  128. Gooneratne NS, Patel NP, Corcoran A. Chronic obstructive pulmonary disease diagnosis and management in older adults. J Am Geriatr Soc. 2010;58(6):1153–62.

    Article  PubMed  Google Scholar 

  129. Maltais F et al. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2008;149(12):869–78.

    PubMed  Google Scholar 

  130. Di Meo F et al. Age does not hamper the response to pulmonary rehabilitation of COPD patients. Age Ageing. 2008;37(5):530–5.

    Article  PubMed  Google Scholar 

  131. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med. 1980;93(3):391–8.

    Google Scholar 

  132. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981;1(8222):681–6.

    Google Scholar 

  133. Casanova C et al. Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. Chest. 2008;134(4):746–52.

    Article  PubMed  Google Scholar 

  134. Chaouat A et al. A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Eur Respir J. 1999;14(5):1002–8.

    Article  PubMed  CAS  Google Scholar 

  135. Gorecka D et al. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax. 1997;52(8):674–9.

    Article  PubMed  CAS  Google Scholar 

  136. Lewis CA et al. Short-burst oxygen immediately before and after exercise is ineffective in nonhypoxic COPD patients. Eur Respir J. 2003;22(4):584–8.

    Article  PubMed  CAS  Google Scholar 

  137. Fletcher EC et al. Survival in COPD patients with a daytime PaO2 greater than 60 mm Hg with and without nocturnal oxyhemoglobin desaturation. Chest. 1992;101(3):649–55.

    Article  PubMed  CAS  Google Scholar 

  138. Ekstrom M, Franklin KA, Strom KE. Increased relative mortality in women with severe oxygen-dependent COPD. Chest. 2010;137(1):31–6.

    Article  PubMed  Google Scholar 

  139. Machado MC et al. Sex differences in survival of oxygen-dependent patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(5):524–9.

    Article  PubMed  Google Scholar 

  140. Naunheim KS et al. Predictors of operative mortality and cardiopulmonary morbidity in the National Emphysema Treatment Trial. J Thorac Cardiovasc Surg. 2006;131(1):43–53.

    Article  PubMed  Google Scholar 

  141. Fishman A et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348(21):2059–73.

    Article  PubMed  Google Scholar 

  142. Sciurba FC et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med. 2010;363(13):1233–44.

    Article  PubMed  CAS  Google Scholar 

  143. Cardoso PF et al. Clinical application of airway bypass with paclitaxel-eluting stents: early results. J Thorac Cardiovasc Surg. 2007;134(4):974–81.

    Article  PubMed  Google Scholar 

  144. Wan IY et al. Bronchoscopic lung volume reduction for end-stage emphysema: report on the first 98 patients. Chest. 2006;129(3):518–26.

    Article  PubMed  Google Scholar 

  145. Strange C et al. Design of the endobronchial valve for emphysema palliation trial (VENT): a non-surgical method of lung volume reduction. BMC Pulm Med. 2007;7:10.

    Article  PubMed  Google Scholar 

  146. Criner GJ et al. Biologic lung volume reduction in advanced upper lobe emphysema: phase 2 results. Am J Respir Crit Care Med. 2009;179(9):791–8.

    Article  PubMed  Google Scholar 

  147. Weiss ES, Merlo CA, Shah AS. Impact of advanced age in lung transplantation: an analysis of United Network for Organ Sharing data. J Am Coll Surg. 2009;208(3):400–9.

    Article  PubMed  Google Scholar 

  148. Bavaria JE et al. Bilateral versus single lung transplantation for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg. 1997;113(3):520–7. discussion 528.

    Article  PubMed  CAS  Google Scholar 

  149. Thabut G et al. Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177(10):1156–63.

    Article  PubMed  Google Scholar 

  150. Ram FS, Lightowler JV, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2003(1); CD004104.

    Google Scholar 

  151. Balami JS, Packham SM, Gosney MA. Non-invasive ventilation for respiratory failure due to acute exacerbations of chronic obstructive pulmonary disease in older patients. Age Ageing. 2006;35(1):75–9.

    Article  PubMed  CAS  Google Scholar 

  152. Bott J et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive airways disease. Lancet. 1993;341(8860):1555–7.

    Article  PubMed  CAS  Google Scholar 

  153. Kramer N et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Respir Crit Care Med. 1995;151(6):1799–806.

    PubMed  CAS  Google Scholar 

  154. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet. 2000;355(9219):1931–5.

    Article  PubMed  CAS  Google Scholar 

  155. Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J. 2008;32(3):796–803.

    Article  PubMed  CAS  Google Scholar 

  156. Hansen-Flaschen J. Chronic obstructive pulmonary disease: the last year of life. Respir Care. 2004;49(1):90–7. discussion 97–8.

    PubMed  Google Scholar 

  157. de Voogd JN et al. Depressive symptoms as predictors of mortality in patients with COPD. Chest. 2009;135(3):619–25.

    Article  PubMed  Google Scholar 

  158. Curtis JR et al. Noninvasive positive pressure ventilation in critical and palliative care settings: understanding the goals of therapy. Crit Care Med. 2007;35(3):932–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors thank Sarah Toombs Smith PhD, ELS, for her help in preparation of the manuscript.

Author information

Authors and Affiliations

  1. Division of Pulmonary and Critical Care Medicine, Departments of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA

    Shiwan K. Shah, Shawn P. E. Nishi & Gulshan Sharma

Authors
  1. Shiwan K. Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shawn P. E. Nishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gulshan Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gulshan Sharma .

Editor information

Editors and Affiliations

  1. School of Medicine, Pulmonary and Critical Care Medicine, Yale University, Cedar Street 330, New Haven, 06520-8057, Connecticut, USA

    Margaret Pisani

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Shah, S.K., Nishi, S.P.E., Sharma, G. (2012). Chronic Obstructive Pulmonary Disease in Older Patients. In: Pisani, M. (eds) Aging and Lung Disease. Respiratory Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-727-3_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-727-3_4

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-726-6

  • Online ISBN: 978-1-60761-727-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation